BlackRock Amends Emergent BioSolutions Stake (17th Update)
Ticker: EBS · Form: SC 13G/A · Filed: Jan 19, 2024 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | SC 13G/A |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a chunk of Emergent BioSolutions, but they're just holding, not shaking things up.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 19, 2024, updating its ownership in Emergent BioSolutions Inc. as of December 31, 2023. This filing, Amendment No. 17, indicates BlackRock's continued significant, but passive, investment in the pharmaceutical company. For investors, this means a major institutional holder remains invested, which can signal confidence, but the passive nature suggests no immediate activist intentions.
Why It Matters
This filing shows BlackRock, a major institutional investor, continues to hold a significant, though passive, stake in Emergent BioSolutions, providing a degree of stability and institutional backing for the stock.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any new significant risks or changes in company control.
Analyst Insight
Investors should note that BlackRock's continued passive ownership suggests no immediate catalyst for significant price movement from this institutional holder, but it does provide a baseline of institutional confidence in Emergent BioSolutions.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Emergent BioSolutions Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 19, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 17 (number) — the specific amendment number for this filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, as indicated by 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 17)'.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as stated under '(1)Names of reporting persons. BlackRock, Inc.' and in the 'FILED BY' section.
What is the subject company of this filing?
The subject company is Emergent BioSolutions Inc., as indicated by 'SUBJECT COMPANY: COMPANY CONFORMED NAME: Emergent BioSolutions Inc.' and '(Name of Issuer) EMERGENT BIOSOLUTIONS INC'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Emergent BioSolutions Inc. is 29089Q105, as listed under '(CUSIP Number) 29089Q105'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 19, 2024 regarding Emergent BioSolutions Inc. (EBS).